Ovarian Reserve and Matrix Metalloproteinases

CompletedOBSERVATIONAL
Enrollment

133

Participants

Timeline

Start Date

August 10, 2021

Primary Completion Date

February 12, 2022

Study Completion Date

March 7, 2022

Conditions
Oxidative StressOvarian Insufficiency, PrimaryOvarian Failure, Premature
Interventions
DIAGNOSTIC_TEST

Prolidase Level

Measurement of venous blood serum level of prolidase enzyme level by ELISA method.

DIAGNOSTIC_TEST

Follicle Stimulating Hormone Level

Measurement of venous blood serum level of follicle stimulating hormone level.

DIAGNOSTIC_TEST

Estradiol Level

Measurement of venous blood serum level of estradiol hormone level.

DIAGNOSTIC_TEST

Proline Level

Measurement of venous blood serum level of proline level.

DIAGNOSTIC_TEST

Hydroxyproline Level

Measurement of venous blood serum level of hydroxyproline level.

DIAGNOSTIC_TEST

Anti-mullerian Hormone Level

Measurement of venous blood serum level of anti-mullerian hormone level.

DIAGNOSTIC_TEST

Antral Follicle Count

Ultrasonographic evaluation of antral follicle count to determine ovarian reserve.

DIAGNOSTIC_TEST

Prolactine Level

Measurement of venous blood serum prolactine hormone level.

DIAGNOSTIC_TEST

Thyroid Stimulating Hormone Level

Measurement of venous blood serum thyroid stimulating hormone level.

Trial Locations (1)

06100

Ankara City Hospital, Ankara

All Listed Sponsors
lead

Ankara City Hospital Bilkent

OTHER

NCT05443282 - Ovarian Reserve and Matrix Metalloproteinases | Biotech Hunter | Biotech Hunter